Article

Rayner's Recently Acquired Ophteis OVD Range and What This Means for Cataract Surgery

Professor Steve Arshinoff and Rayner CEO Tim Clover announce Rayner's recent acquisition of the Ophteis OVD range at the Company's celebratory event, held at the 2015 ESCRS in Barcelona.

Redirect to video article

 

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Alcon agrees to purchase LENSAR
March 25th 2025

Alcon agrees to purchase LENSAR

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

ZEISS VISULAS Combi availability expands to Canada
March 24th 2025

ZEISS VISULAS Combi availability expands to Canada

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial
March 24th 2025

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial

Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis
March 24th 2025

Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis

© 2025 MJH Life Sciences

All rights reserved.